stoxline Quote Chart Rank Option Currency Glossary
  
Altamira Therapeutics Ltd. (EARS)
3.045  -0.055 (-1.77%)    07-26 00:00
Open: 3.08
High: 3.09
Volume: 174,066
  
Pre. Close: 3.1
Low: 3.0004
Market Cap: 4(M)
Technical analysis
2024-03-28 4:51:09 PM
Short term     
Mid term     
Targets 6-month :  2.79 1-year :  3.1
Resists First :  2.39 Second :  2.65
Pivot price 2.11
Supports First :  1.96 Second :  1.63
MAs MA(5) :  2.06 MA(20) :  2.16
MA(100) :  2.01 MA(250) :  2.38
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  12.1 D(3) :  13.4
RSI RSI(14): 47.8
52-week High :  3.37 Low :  1.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ERAS ] has closed above bottom band by 31.6%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.6 - 2.61 2.61 - 2.62
Low: 1.99 - 2.01 2.01 - 2.02
Close: 2.04 - 2.06 2.06 - 2.08
Company Description

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Headline News

Tue, 05 Dec 2023
Altamira Therapeutics to Host Investor & Business Update Call on December 11th - Yahoo Finance

Wed, 29 Nov 2023
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - Yahoo Finance

Fri, 17 Nov 2023
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business - Yahoo Finance

Thu, 15 Jun 2023
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome - Yahoo Finance

Mon, 10 Apr 2023
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with ... - Yahoo Finance

Fri, 21 Oct 2022
Altamira finds buyer for Zilentin inner ear unit so Swiss biotech can go all-in on RNA - Fierce Biotech

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 151 (M)
Shares Float 85 (M)
Held by Insiders 23.3 (%)
Held by Institutions 54.7 (%)
Shares Short 9,900 (K)
Shares Short P.Month 10,220 (K)
Stock Financials
EPS -1.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21.1 %
Return on Equity (ttm) -65.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -103 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -1.2
PEG Ratio 0.1
Price to Book value 0.91
Price to Sales 0
Price to Cash Flow -3.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android